Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Australia is putting serious money into homegrown drug development. A WEHI-led project has secured $7 million in federal funding — part of a $10.6 million total investment — to expand the National Drug Discovery Centre and give researchers access to cutting-edge screening technologies. The goal: turn promising lab discoveries into real treatments, faster.
Australia is doubling down on its biomedical ambitions. The Walter and Eliza Hall Institute of Medical Research (WEHI) has landed a $7 million grant from the Medical Research Future Fund (MRFF), which — combined with ~$3.6 million in co-investment from WEHI — brings the total initiative to $10.6 million. The funding will expand the National Drug Discovery Centre (NDDC), Australia's top small-molecule screening facility, and launch a new Discovery Access program to give universities, research institutes, and small businesses subsidized access to high-tech drug screening tools.
The NDDC, established in 2020, already uses pharmaceutical-grade robotic technologies to screen drug candidates — having screened over 10 million compounds across 30+ projects. The expanded program will dramatically scale that up, enabling researchers to screen more than 20 million virtual compounds and 300,000 physical compounds over the next three years.
By the Numbers:
Why it matters: A major bottleneck in drug development is the early-stage identification of viable drug candidates — a step that typically requires expensive infrastructure only large pharma companies can afford. This investment aims to democratize access for Australian researchers, potentially accelerating treatments for diseases with significant unmet need while strengthening the country's biotech sector.
